home / stock / cvm / cvm articles
CEL-SCI Corp (NASDAQ:CVM) shares are trading higher by 18.6% to $1.98 during Wednesday’s session after the company received positive feedback...
CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 13.9% to $2.46 Friday morning after the company priced an offering of 3.875 million sh...
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow...
News, Short Squeeze, Breakout and More Instantly...
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 ...
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and D...